Control
so complete,
it's like
you're
always
there

Defend their wounds between weekly debridements with PuraPly® AM
The unique combination of native, cross-linked ECM + broad-spectrum PHMB provides a sustained antimicrobial barrier to keep you in command of the healing environment all week long.1-3

key barriers to healing

Patient noncompliance

Inability and/or unwillingness to adhere to treatment plans for chronic wounds is a major barrier to healing.

  • Many patients with lower-extremity chronic wounds are unable to change their own dressings4
  • Patients with chronic wounds fear touching their own wounds and prefer that their doctor or nurse exclusively control their care4,5
  • When treatments do force patients to change their own primary dressings, wounds can be exposed to bacteria in the home that can lead to contamination

Healthcare studies
show that patientadherence improves
when treatments require
less intervention.6

BIOBURDEN & BIOFILM

Excessive bioburden and biofilm trigger a continuous inflammatory response that stalls wound healing7

EXCESS MMPs

The bacteria in biofilm generate excess and imbalanced MMPs that can break down the ECM8,9

ecm degrAdation

Degradation prevents proper formation of the ECM, granulation tissue, and the scaffold needed for cell migration10

ECM=extracellular matrix; MMP=matrix metalloproteinaises; PHMB=polyhexamethylene biguanide

Weekly sharp debridement is essential but, alone, does not control microbial growth or prevent biofilm re-formation.11

Take control with puraply am

Hear a message from Dr. Andrew Rader about approaching wound care during the current challenges of the COVID-19 crisis.

For questions, contact your Organogenesis TissueRegeneration Specialist

The advanced antimicrobial barrier with native, cross-linked ECM + broad-spectrum PHMB

sharp debridement + puraply am

  • Provides optimal foundation of care for controlling bioburden and preventing biofilm re-formation12-14
  • Produces a sustained antimicrobial barrier effect between weekly debridements1,2
  • Eliminates the need for at-home primary dressing changes by the patient and/or caregiver3

HELPS SUPPORT HEALING15,16

Unlike fragmented, reconstituted collagen:
  • Native ECM inhibits a wider range of MMPs, helping to address the proteolytic environment that stalls wounds17
  • The cross-linked, dual layers of PuraPly AM resist ECM degradation in the wound, supporting persistence between debridements2
  • The dual layers of PuraPly AM maximize surface area for PHMB saturation3,8,13

PROACTIVELY DISRUPTS BIOBURDEN3,13,14

Unlike silver dressings, PHMB:
  • Won't damage key cells (eg, fibroblasts) involved in wound healing18
  • Features high tissue compatibility and low cytotoxicity12,14,19
  • Has no known instances of bacteria acquiring resistance12-14,20

THE POWER OF PLUS

Only PuraPly AM features the unique combination of native, cross-linked ECM + broad-spectrum PHMB to:
  • Provide a sustained antimicrobial barrier effect1,2
  • Help prevent biofilm re-formation2
  • Act as a bridge between weekly debridements2
  • Keep you in control of the healing environment

sharp debridement + puraply am

  • Provides optimal foundation of care for controlling bioburden and preventing biofilm re-formation12-14
  • Produces a sustained antimicrobial barrier effect between weekly debridements1,2
  • Eliminates the need for at-home primary dressing changes by the patient and/or caregiver3

HELPS SUPPORT HEALING15,16

Unlike fragmented, reconstituted collagen:
  • Native ECM inhibits a wider range of MMPs, helping to address the proteolytic environment that stalls wounds17
  • The cross-linked, dual layers of PuraPly AM resist ECM degradation in the wound, supporting persistence between debridements2
  • The dual layers of PuraPly AM maximize surface area for PHMB saturation3,8,13

PROACTIVELY DISRUPTS BIOBURDEN3,13,14

Unlike silver dressings, PHMB:
  • Won't damage key cells (eg, fibroblasts) involved in wound healing18
  • Features high tissue compatibility and low cytotoxicity12,14,19
  • Has no known instances of bacteria acquiring resistance12-14,20

THE POWER OF PLUS

Only PuraPly AM features the unique combination of native, cross-linked ECM + broad-spectrum PHMB to:
  • Provide a sustained antimicrobial barrier effect1,2
  • Help prevent biofilm re-formation2
  • Act as a bridge between weekly debridements2
  • Keep you in control of the healing environment

confirmation of control

Substantially reduced MRSA vs PriMatrix® Ag, Endoform, and untreated control1

Objective:

Deep dermal porcine wound model study to evaluate the ability of PuraPly AM to reduce biofilm-associated bacteria (MRSA USA300, a clinically virulent strain of Staphylococcus aureus) vs 3 other treatment groups: PriMatrix Ag, Endoform, and untreated control

Preliminary results*1:

  • >98% reduction of MRSA counts compared to baseline
  • >96% reduction of MRSA counts vs untreated control on all assessment days
  • Largest reduction of MRSA counts vs any of the other treatment groups
*After treatment application, bacteria counts were assessed on days 2, 3, 4, 7, 10, and 14. This was a preliminary study with a small sample size, so these observational results are not statistically powered conclusions.

PuraPly AM was the only product to achieve

>80 % reduction in MRSA

after debridement on all assessment days1

In a prospective case series to assess ability of PuraPly AM to manage bioburden, support granulation tissue formation, and support wound closure over 12 weeks, PuraPly AM was proven to reduce wound size in chronic wounds that failed ~2 years of prior therapies.15

Prior Therapies

103 weeks

PuraPly AM

12 weeks

After ~2 years of prior therapies in refractory chronic wounds, PuraPly AM reduced size or closed wounds in ≤12 weeks15

Reduced wound area for

73.2 %

of wounds

30/41 wounds over 12 weeks15

SUPPORTED WOUND HEALING

36.6% (15/41) achieved complete closure15

6.7  weeks

MEAN TIME TO CLOSURE

for the 15/41 wounds that achieved complete closure15

INCREASED GRANULATION TISSUE

observed with healing of wounds15

In a Real-World Effectiveness Study of PuraPly AM on Wounds (RESPOND) postmarketing open-label, prospective, observational multicenter study, PuraPly AM was proven to consistently improve healing trajectories in a variety of chronic wounds.21

Patients with final data as of January 26, 2018.

Reduced wound area for

90 %

of wounds

57/63 wounds over 4-month study period21

SUPPORTED WOUND HEALING

68.3% (43/63) achieved complete closure21

5.0 weeks

MEAN TIME TO CLOSURE

for the 43/63 wounds that achieved complete closure21

wounds
come in all
shapes and sizes

So does PuraPly AM, helping you manage a wide variety of acute and chronic wounds.3

Abrasions, lacerations, second-degree burns, skin tears. §Donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence.

Product size(unique device identifier number)

  • 8×16 cmPURAPLYAM-COM 8×16(00618474000121)
  • 6×9 cmPURAPLYAM-COM 6×9(00618474000114)
  • 5×5 cmPURAPLYAM-COM 5×5(00618474000107)
  • 3.02×3.02 cmPURAPLYAM-COM 3.02×3.02(00618474000299)
  • 3.76×3.76 cmPURAPLYAM-COM 3.76×3.76(00618474000305)
  • 2×4 cmPURAPLYAM-COM 2×4(00618474000091)
  • 2.05×3.05 cmPURAPLYAM-COM 2.05×3.05(00618474000329)
  • 2×2 cmPURAPLYAM-COM 2×2(00618474000084)
  • 1.6 cmPURAPLYAM-COM 1.6 DISC(00618474000190)

READY TO TAKE CONTROL OF THE HEALING ENVIRONMENT?

Talk to an Organogenesis Tissue Regeneration Specialist about the advanced antimicrobial barrier with native, cross-linked ECM + broad-spectrum PHMB that keeps you in command between weekly debridements.1-3

I am a:

Organogenesis will not sell, rent, or otherwise distribute your name or any personally identifiable information outside of Organogenesis and its agents. Organogenesis will only use your information in accordance with our Privacy Policy.

Thank you. We are processing your request... We are unable to process your request at this time. Please try again later.

Thank you.

We have received your information and will contact you shortly.

solutions
and support

product portfolio

Our advanced wound care solutions empower patients and providers throughout the healing process.

See all products

circle of care

Our comprehensive program provides the highest-quality customer service and reimbursement support.

See program details

References:1. Data on file. PDR-0001. Organogenesis Inc. 2. Data on file. PDR-0002. Organogenesis Inc. 3. PuraPly Antimicrobial [package insert]. Canton, MA: Organogenesis Inc; 2015. 4. Fife C, et al. Wounds. 2007;19(10):255-257. 5. Zulec M, et al. Int J Environ Res Public Health. 2019;16(4):e559. 6. Atreja A, et al. MedGenMed. 2005;7(1):4. 7. Frykberg RG, et al. Adv Wound Care. 2015;4(9):560-582. 8. Carpenter S, et al. Wounds. 2016;28(6 suppl):S1-S20. 9. Gibson D, et al. Wounds Int. 2009;1(1):1-6. 10. Brett D. Wounds. 2008;20(12):347-356. 11. Schultz G, et al. Wound Repair Regen. 2017;25(5):744-757. 12. Hübner NO, et al. Skin Pharmacol Physiol. 2010;23(1 suppl):17-27. 13. Brantley J, et al. Wounds Int. 2016;7(3):1-5. 14. Gilbert P, et al. J Appl Microbiol. 2005;99(4):703-715. 15. Oropallo AR. Plast Reconstr Surg Glob Open. 2019;7:e2047. 16. Lintzeris D, et al. Wounds. 2018;30(3):72-78. 17. Negron L, et al. Int Wound J. 2014;11(4):392-397. 18. Zou SB, et al. Int Wound J. 2013;10(3):306-312. 19. Sood A, et al. Adv Wound Care. 2014;3(8):511-529. 20. Sim W, et al. Antibiotics. 2018;7(4):93. 21. Bain MA, et al. Plast Reconstr Surg Glob Open. 2019;7(6):e2251.